Results 31 to 40 of about 912,051 (307)

An Overview on the Development of mRNA-Based Vaccines and Their Formulation Strategies for Improved Antigen Expression In Vivo

Vaccines, 2021
The mRNA-based vaccine approach is a promising alternative to traditional vaccines due to its ability for prompt development, high potency, and potential for secure administration and low-cost production.
Md. Motiar Rahman, Nan Zhou, Jiandong Huang   +2 more
doaj   +1 more source

Delivery Strategies for mRNA Vaccines [PDF]

Pharmaceutical Medicine, 2022
The therapeutic potential for messenger RNA (mRNA) in infectious diseases and cancer was first realized almost three decades ago, but only in 2018 did the first lipid nanoparticle-based small interfering RNA (siRNA) therapy reach the market with the United States Food and Drug Administration (FDA) approval of patisiran (Onpattro™) for hereditary ATTR ...
Sivakumar Ramachandran, Soumya Ranjan Satapathy, Tathagata Dutta   +2 more
openaire   +2 more sources

Stability Modelling of mRNA Vaccine Quality Based on Temperature Monitoring throughout the Distribution Chain

Pharmaceutics, 2022
The vaccine distribution chains in several low- and middle-income countries are not adequate to facilitate the rapid delivery of high volumes of thermosensitive COVID-19 mRNA vaccines at the required low and ultra-low temperatures. COVID-19 mRNA vaccines
Zoltán Kis
doaj   +1 more source

Structural characterization of Lysimachia christinae acidic polysaccharides and investigation of its adjuvant efficacy for mRNA vaccines

Materials & Design
The limited availability of effective adjuvants for mRNA vaccines necessitates the exploration of novel immunostimulatory agents. Here, we isolated and structurally characterized an acidic polysaccharide (LCAP) from the traditional Chinese herb ...
Chongyu Tian, Jiaojiao Nie, Yue Chen, Chao Dong, Mingshuo Ji, Yujing Liu, Jiaqi Nie, Xinhao Zhang, Jixiang Sun, Jiahan Gang, He Huang, Yongfei Zhou, Lin Jin, Wanbo Tai   +13 more
doaj   +1 more source

Safety Following COVID-19 Booster Vaccine with BNT162b2 Compared to mRNA-1273 in Solid Cancer Patients Previously Vaccinated with ChAdOx1 or CoronaVac

Vaccines, 2023
Safety data following the COVID-19 booster mRNA vaccine in solid cancer patients are scarce. We prospectively evaluated adverse events after a booster dose of the BNT162b2 vaccine as compared to the mRNA-1273 vaccine in solid malignancy patients who had ...
Passakorn Wanchaijiraboon, Panot Sainamthip, Nattaya Teeyapun, Sutima Luangdilok, Yong Poovorawan, Nasamon Wanlapakorn, Suebpong Tanasanvimon, Virote Sriuranpong, Thiti Susiriwatananont, Nicha Zungsontiporn, Nussara Pakvisal   +10 more
doaj   +1 more source

Preclinical assessment of a new live attenuated Mycobacterium tuberculosis Beijing-based vaccine for tuberculosis

, 2020
Tuberculosis still claims more lives than any other pathogen, and a vaccine better than BCG is urgently needed. One of the challenges for novel TB vaccines is to protect against all Mycobacterium tuberculosis lineages, including the most virulent ones ...
권기웅, 신성재
core   +1 more source

Formulation development of a stable influenza recombinant neuraminidase vaccine candidate

Human Vaccines & Immunotherapeutics
Current influenza vaccines could be augmented by including recombinant neuraminidase (rNA) protein antigen to broaden protective immunity and improve efficacy.
Bing Li, Irina V. Ustyugova, Lisa Szymkowicz, Shaolong Zhu, Marin Ming, Karen Y. Y. Fung, Guadalupe Cortés, D. Andrew James, Michael Hrynyk, Nausheen Rahman, Roger H. Brookes, Salvador F. Ausar   +11 more
doaj   +1 more source

COVID-19 mRNA vaccines

Journal of Genetics and Genomics, 2021
The ongoing COVID-19 pandemic and its unprecedented global societal and economic disruptive impact highlight the urgent need for safe and effective vaccines. Taking substantial advantages of versatility and rapid development, two mRNA vaccines against COVID-19 have completed late-stage clinical assessment at an unprecedented speed and reported positive
Huang, Qingrui, Zeng, Jiawei, Yan, Jinghua   +2 more
openaire   +2 more sources

Primary and booster immune responses to SA14-14-2 Japanese encephalitis vaccine in Korean infants

, 1999
Attenuated SA14-14-2 Japanese encephalitis (JE) vaccine has been administered safely and effectively to more than 100 million children in China since 1988 and recently, licensure of the vaccine in Korea has been sought.
박민수
core   +1 more source

Adverse events following COVID‐19 mRNA vaccines: A systematic review of cardiovascular complication, thrombosis, and thrombocytopenia

Immunity, Inflammation and Disease, 2023
Background and Objectives Since publishing successful clinical trial results of mRNA coronavirus disease 2019 (COVID‐19) vaccines in December 2020, multiple reports have arisen about cardiovascular complications following the mRNA vaccination. This study
Farah Yasmin, Hala Najeeb, Unaiza Naeem, Abdul Moeed, Abdul Raafe Atif, Muhammad Sohaib Asghar, Nayef Nimri, Maryam Saleem, Dhrubajyoti Bandyopadhyay, Chayakrit Krittanawong, Mohammed Mahmmoud Fadelallah Eljack, Muhammad Junaid Tahir, Fahad Waqar   +12 more
doaj   +1 more source